10x Genomics (TXG) Cash & Current Investments (2018 - 2026)

10x Genomics has reported Cash & Current Investments for 9 years, with the latest figure at $539.8 million in Q1 2026.

• Quarterly Cash & Current Investments rose 26.46% year-over-year to $539.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $539.8 million (up 26.46% YoY) and the FY2025 annual result came in at $523.4 million, up 33.05% from the prior year.
• Cash & Current Investments advanced to $539.8 million in Q1 2026 per TXG's latest filing, from $523.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $539.8 million in Q1 2026 and troughed at $222.4 million in Q4 2022.
• A 5-year average of $406.2 million and a median of $398.2 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 62.21% in 2022, then surged 74.79% in 2023.
• Over 5 years, Cash & Current Investments stood at $222.4 million in 2022, then soared by 74.79% to $388.7 million in 2023, then rose by 1.21% to $393.4 million in 2024, then surged by 33.05% to $523.4 million in 2025, then gained by 3.14% to $539.8 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $539.8 million, $523.4 million, and $482.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.